Beam Therapeutics Inc. (BEAM)

40.42 +0.02 (+0.05%) At close: 04:00PM EDT

Beam Therapeutics Inc.

238 Main Street
9th Floor
Cambridge, MA 02142
United States
857 327 8775
https://www.beamtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 394

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John M. Evans M.B.A.	CEO & Director	1.02M	1.62M	1978
Dr. Giuseppe Ciaramella Ph.D.	Pres & Chief Scientific Officer	890.79k	14.85M	1969
Ms. Terry-Ann Burrell M.B.A.	CFO & Treasurer	687.52k	9.18M	1977
Dr. Feng Zhang Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. David R. Liu Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Nicole Gaudelli Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Alexis Komor Ph.D.	Co-Founder	N/A	N/A	N/A
Ms. Suzanne Fleming	Chief Accounting Officer	N/A	N/A	1961
Mr. Brian Riley	Sr. VP of Technical Operations	N/A	N/A	1977

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Corporate governance

Beam Therapeutics Inc.’s ISS governance QualityScore as of 1 June 2022 is 7. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.